Company News_Press Release_InxMed-Biotech_Pipeline_FAK inhibitor

30

2023-08

2023-08-30

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC

Nanjing, China, Aug 30, 2023 InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors，announced today the first-in-class ADC OMTX705 has obtained the IND (Investigational New Drug) approval from China National Medical Products Administration (NMPA) recently.

18

2022-10

2022-10-18

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022

NANJING, China, Oct 18, 2022 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label, phase Ib trial evaluating the efficacy and safety of IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), alone or in combination with cobimetinib (Cobi, an approved mitogen-activated protein kinase [MEK] inhibitor from Roche) in patients with Uveal Melanoma (UM) and NRAS-mutant melanoma. The clinical data is being presented in the form of poster at the Society for Melanoma Research (SMR) 19th International Congress from October 17-20, 2022 (Abstract #: P-141). The released data showed that IN10018 in combination with Cobi demonstrated promising antitumor activities and acceptable safety profile in patients with metastatic melanoma. InxMed has entered into a global clinical collaboration with Roche to evaluate IN10018 in combination with Cobi before.

08

2022-09

2022-09-08

InxMed Announces First Patient Dosed in Pivotal Phase 2 Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer

NANJING, China, Sep 8th, 2022 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting drug resistance and metastasis for hard-to-treat solid tumors, today announced the dosing of the first patient in its Phase 2 pivotal study evaluating IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant recurrent ovarian cancer (PROC).

30

2022-05

2022-05-30

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Platinum-Resistant Recurrent Ovarian Cancer at ASCO 2022

NANJING, China, May 30, 2022 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label phase Ib trial evaluating the efficacy and safety of IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant recurrent ovarian cancer (PROC), will be presented in the form of poster at the upcoming 2022 annual meeting of American Society of Clinical Oncology (ASCO) from June 3, 2022 to June 7, 2022. Abstract was published on the ASCO's website（Abstract #：5567）. The data showed that patients receiving combination of IN10018 with PLD demonstrated promising antitumor activities and manageable safety profile in PROC patients, with a high overall response rate (ORR) of 56.7%（Poster #：445）.

09

2022-05

2022-05-09

InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers

NANJING, China, May 9, 2022 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in Series B+ Financing. The Series B+ was funded by Hyfinity Investments.

14

2022-04

2022-04-14

InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy Designation by the China National Medical Products Administration for Platinum-Resistant Ovarian Cancer

NANJING, China, April 14, 2022 -- InxMed Co., Ltd. announced that IN10018, its focal adhesion kinase (FAK) inhibitor, had been granted with Breakthrough Therapy Designation by the China National Medical Products Administration. This designation is based on the results of a Phase Ib/II clinical trial of IN10018 for platinum-resistant ovarian cancer, with the proposed indication for the treatment of platinum-resistant ovarian cancer in combination with PEG-liposomal doxorubicin. InxMed plans to disclose more data on IN10018 at the Annual Meeting of the American Society of Clinical Oncology in June 2022 and initiate a pivotal trial in the second half of the year.

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022

InxMed Announces First Patient Dosed in Pivotal Phase 2 Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Platinum-Resistant Recurrent Ovarian Cancer at ASCO 2022

InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers

InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy Designation by the China National Medical Products Administration for Platinum-Resistant Ovarian Cancer

QUICK LINKS

CONTACT US

MESSAGE